Promising inhibitors targeting Mpro: an ideal strategy for anti- SARS-CoV-2 drug discovery
Fecha
2020Autor
Chen, Yi
Wang, Guan
Ouyang, Liang
Resumen
Recently, Dai W et al. published a study on Science,1 in which
the two lead compounds 11a and 11b were designed and
synthesized based on the features of a key enzyme Mpro of SARSCoV-2 (Fig. 1). In particular, compound 11a is a potential drug
candidate for coronavirus disease 2019 (COVID-19) with strong
anti-SARS-CoV-2 infection activity, good pharmacokinetics characteristics, and low toxicity.
Since December 2019, the outbreak of COVID-19 caused by
SARS-CoV-22 has caused a serious global public health emergency.
So far, the global epidemic is still in the outbreak stage, and the
number of new confirmed cases every day has exceeded 100,000
for several days. At present, the main drugs used clinically include
interferon-alpha, lopinavir/ritonavir, ribavirin, arbidol, etc. However, these drugs are facing huge controversy due to the large
side effects or the lack of clinical verifications of the therapeutic
effects.3 Therefore, clarifying the origin and pathogenesis of
pneumonia and decoding the key targets against SARS-CoV-2 are
the cornerstone to design and discover safe and effective
antivirus drugs.
Palabras clave
Targeting Mpro; Anti SARS-CoV-2; Drug discoveryEnlace al recurso
https://doi.org/10.1038/s41392-020-00291-8Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.